Literature DB >> 25802103

[Non-muscle-invasive high-grade bladder cancer].

G Gakis1, A Stenzl, T Horn, J E Gschwend, W Otto, M Burger.   

Abstract

BACKGROUND: Non-muscle-invasive bladder cancer with a low-grade differentiation represents a special challenge.
METHOD: Although urine cytology is still the most reliable and effective urine-based marker and there are no substantial novel aspects in this field, photodynamic diagnostics have the most important value in transurethral resection of the bladder (TURB) of high-grade T1 tumors and new techniques, such as hybrid knife TURB are coming up. The histopathological assessment of T1 tumors can be supplemented by a description of the exact penetration depth, so-called substaging and the invasion pattern.
RESULTS: Intravesicle therapy with Bacillus Calmette-Guèrin (BCG) represents the gold standard and a pillar of bladder-preserving therapy and should be planned as maintenance therapy for at least 1 year. With the right risk constellation cystectomy is a safe and proven concept for high-grade bladder cancer, even without proof of muscle invasion.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25802103     DOI: 10.1007/s00120-015-3774-7

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  44 in total

1.  A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival.

Authors:  Osama Shahin; George N Thalmann; Cyrill Rentsch; L Mazzucchelli; U E Studer
Journal:  J Urol       Date:  2003-01       Impact factor: 7.450

2.  Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.

Authors:  Joan Palou; Richard J Sylvester; Oscar Rodríguez Faba; Rubén Parada; Juan A Peña; Ferran Algaba; Humberto Villavicencio
Journal:  Eur Urol       Date:  2011-10-25       Impact factor: 20.096

3.  Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.

Authors:  Cyrill A Rentsch; Frédéric D Birkhäuser; Claire Biot; Joël R Gsponer; Aurélie Bisiaux; Christian Wetterauer; Micheline Lagranderie; Gilles Marchal; Mickael Orgeur; Christiane Bouchier; Alexander Bachmann; Molly A Ingersoll; Roland Brosch; Matthew L Albert; George N Thalmann
Journal:  Eur Urol       Date:  2014-03-12       Impact factor: 20.096

4.  Influence of renal excretory function on the performance of urine based markers to detect bladder cancer.

Authors:  Tilman Todenhöfer; Jörg Hennenlotter; Marc Witstruk; Georgios Gakis; Stefan Aufderklamm; Ursula Kuehs; Arnulf Stenzl; Christian Schwentner
Journal:  J Urol       Date:  2011-11-16       Impact factor: 7.450

Review 5.  The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer.

Authors:  Wolfgang Otto; Stefan Denzinger; Hans-Martin Fritsche; Maximilian Burger; Wolf F Wieland; Ferdinand Hofstädter; Arndt Hartmann; Simone Bertz
Journal:  BJU Int       Date:  2010-08-12       Impact factor: 5.588

Review 6.  Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis.

Authors:  Baerin B Houghton; Venu Chalasani; Dickon Hayne; Peter Grimison; Christopher S B Brown; Manish I Patel; Ian D Davis; Martin R Stockler
Journal:  BJU Int       Date:  2012-12-17       Impact factor: 5.588

7.  Prognostic value of histopathological tumour growth patterns at the invasion front of T1G3 urothelial carcinoma of the bladder.

Authors:  Stefan Denzinger; Maximilian Burger; Hans-Martin Fritsche; Simone Bertz; Ferdinand Hofstädter; Wolf F Wieland; Arndt Hartmann; Wolfgang Otto
Journal:  Scand J Urol Nephrol       Date:  2009

8.  An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.

Authors:  Per-Uno Malmström; Richard J Sylvester; David E Crawford; Martin Friedrich; Susanne Krege; Erkki Rintala; Eduardo Solsona; Savino M Di Stasi; J Alfred Witjes
Journal:  Eur Urol       Date:  2009-04-24       Impact factor: 20.096

9.  The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.

Authors:  Jorg R Oddens; Richard J Sylvester; Maurizio A Brausi; Wim J Kirkels; Cees van de Beek; George van Andel; Theo M de Reijke; Stephen Prescott; J Alfred Witjes; Willem Oosterlinck
Journal:  Eur Urol       Date:  2014-06-16       Impact factor: 20.096

10.  Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy.

Authors:  Derya Tilki; Shahrokh F Shariat; Yair Lotan; Michael Rink; Pierre I Karakiewicz; Mark P Schoenberg; Seth P Lerner; Guru Sonpavde; Arthur I Sagalowsky; Amit Gupta
Journal:  BJU Int       Date:  2012-11-26       Impact factor: 5.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.